Listen
TRULICITY (dulaglutide), antidiabetic
DIABETOLOGY - New medicinal product
Opinions on drugs -
Posted on
Sep 17 2015
Reason for request
Inclusion
No added clinical benefit demonstrated in dual therapy with metformin and in triple therapy with metformin and insulin or with metformin and a sulfonylurea.
No clinical benefit in monotherapy or in dual therapy with insulin.
- TRULICITY is a GLP-1 analogue with Marketing Authorisation in the treatment of type 2 diabetes in monotherapy or in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- Studies versus other diabetes medicines have not shown a clinical benefit for TRULICITY in terms of efficacy or safety.
Clinical Benefit
| Substantial |
- |
| Insufficient |
Therapeutic use
- |
-
English version
Contact Us
Évaluation des médicaments
